These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 26641535)

  • 1. Once-daily glycopyrronium bromide (Seebri Breezhaler(®)) for the treatment of chronic obstructive pulmonary disease (COPD).
    Ulrik CS
    Expert Opin Pharmacother; 2015; 16(17):2653-9. PubMed ID: 26641535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease.
    Carter NJ
    Drugs; 2013 May; 73(7):741-53. PubMed ID: 23677802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit.
    Ulrik CS
    Int J Chron Obstruct Pulmon Dis; 2012; 7():673-8. PubMed ID: 23055716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Glycopyrronium bromide is a long-acting inhaled anticholinergic in the treatment of severe COPD].
    Ulrik CS
    Ugeskr Laeger; 2013 Aug; 175(35):1946-8. PubMed ID: 23978116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.
    Buhl R; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2012; 7():729-41. PubMed ID: 23118536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.
    Riario-Sforza GG; Ridolo E; Riario-Sforza E; Incorvaia C
    Expert Rev Respir Med; 2015 Feb; 9(1):23-33. PubMed ID: 25547422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.
    Molimard M; D'Andrea P
    Expert Rev Clin Pharmacol; 2013 Sep; 6(5):503-17. PubMed ID: 23971870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.
    Rossi A; Zanardi E; Poletti V; Cazzola M
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1383-92. PubMed ID: 26229457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden.
    Costa-Scharplatz M; Ställberg B; Goyal P; Asukai Y; Gruenberger JB; Price D
    Appl Health Econ Health Policy; 2015 Dec; 13(6):637-45. PubMed ID: 26324401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel model-based approach for dose determination of glycopyrronium bromide in COPD.
    Arievich H; Overend T; Renard D; Gibbs M; Alagappan V; Looby M; Banerji D
    BMC Pulm Med; 2012 Dec; 12():74. PubMed ID: 23217058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ▾Glycopyrronium for COPD.
    Drug Ther Bull; 2013 Jun; 51(6):66-8. PubMed ID: 23744364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
    Prakash A; Babu KS; Morjaria JB
    Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
    Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
    Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease.
    Frampton JE
    Drugs; 2014 Mar; 74(4):465-88. PubMed ID: 24604791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD - A randomised, multicentre, crossover trial.
    Watz H; Mailänder C; May C; Baier M; Kirsten AM
    Pulm Pharmacol Ther; 2017 Feb; 42():13-20. PubMed ID: 27940287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting muscarinic antagonists for the prevention of exacerbations of chronic obstructive pulmonary disease.
    Jones PW
    Ther Adv Respir Dis; 2015 Jun; 9(3):84-96. PubMed ID: 25801643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease.
    Vogelmeier C; Banerji D
    Ther Adv Respir Dis; 2011 Jun; 5(3):163-73. PubMed ID: 21511677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety of glycopyrrolate/eFlow
    Ferguson GT; Goodin T; Tosiello R; Wheeler A; Kerwin E
    Respir Med; 2017 Nov; 132():251-260. PubMed ID: 28919143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tiotropium on COPD exacerbations: A systematic review.
    Halpin DM; Vogelmeier C; Pieper MP; Metzdorf N; Richard F; Anzueto A
    Respir Med; 2016 May; 114():1-8. PubMed ID: 27109805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
    Ficker JH; Rabe KF; Welte T
    Pulm Pharmacol Ther; 2017 Aug; 45():19-33. PubMed ID: 28389258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.